Skip to content

ViralLoop

Your next post already worked.

←

Write from this board Add posts Share

AllXLinkedInInstagramTikTok

FilterOrderGridTableSelect

Loading the board

Incyte — how they publish · ViralLoop

Incyte — how they publish

Remix this board

10 posts · curated by ViralLoop

80 posts from @Incyte, Sep 2025 to Aug 2026: a typical post earns 2 likes. That is more than 19% of the 275 other S&P 500 companies we hold content for. About 1 in 6 of their posts opens with a number. Posts with an image or video earn a median of 2 likes (73 posts); text alone 4 likes (7).

AllX LinkedIn Instagram TikTok

We are excited to announce a strategic collaboration with @EdisonSci to employ the Kosmos AI platform across Incyte's discovery and development lifecycle. Read more. t.co

Opens with an observation

20 likes2 repliesIn reviewAIX3mo ago

We’re proud to share that we have been named to LinkedIn’s inaugural Philadelphia Top Companies list. This recognition reflects the people behind our work. A team united by purpose, committed to advancing science and focused on making a difference for patients. #SolveOn

Opens with an observation

7 likes3 repliesIn reviewHiringX3mo ago

We’ve announced positive topline results from the Phase 3 frontMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Read our press release to learn more. t.co

Opens with an observation

7 likes0 repliesIn reviewScienceX8mo ago

Incyte announced an agreement to acquire Vega Therapeutics, a wholly owned subsidiary of @Star_biotech, strengthening our hematology portfolio and expanding our work into bleeding disorders. Read more: t.co

Opens with an observation

6 likes0 repliesIn reviewGeneralX3mo ago

Incyte is heading to the @hsforg Symposium on Hidradenitis Suppurativa Advances (SHSA), where we are looking forward to engaging with the dermatology community and sharing our latest findings. #SHSA2025 t.co

Opens with an observation

5 likes2 repliesIn reviewGeneralX10mo ago

We’re focused on building a portfolio of scientifically differentiated compounds designed to make a meaningful impact for patients. Learn more about von Willebrand disease (VWD), the most common inherited bleeding disorder, and the data presented at this year’s #ISTH2026

Opens with an observation

4 likes0 repliesIn reviewGeneralX1mo ago

For the first time since acquiring VGA039 (latarcibart), we’re sharing data at the @isth Congress. We look forward to connecting with researchers, clinicians and partners from around the world as we seek to advance care for patients.

Opens with a number

4 likes0 repliesIn reviewGeneralX2mo ago

Today at the American Society of Clinical Oncology® (@ASCO) Annual Meeting we shared new data from the pivotal frontMIND trial in patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL), simultaneously published in @TheLancet. Learn more. #ASCO26

Opens with an announcement

4 likes0 repliesIn reviewScienceX3mo ago

Incyte and @genesismolai are expanding our collaboration designed to accelerate the discovery of potential new medicines. Learn more. t.co

Opens with an observation

4 likes0 repliesIn reviewGeneralX3mo ago

Excited for our partnership with Edison Scientific. Read more here: t.co

Opens with an observation

4 likes0 repliesIn reviewGeneralX3mo ago

Boards are how ViralLoop learns your taste — save posts you admire, and turn the collection into content that sounds like you.

Start your own board